Loading your page…

Pharmaceutical group

Henlius

8 medicines3 countries

A group of 2 companies with 8 medicines in 3 countries.

Its medicines

Group structure

2 companies in 0 countries

Headquarters not stated2

Shanghai Henlius Biotech, Inc.Authorisation holder · 7 medicines · listed in Canada, United States
Shanghai Henlius Biopharmaceutical Co. Ltd.Manufacturer · 1 medicine · listed in Brazil, Saudi Arabia +1

Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.

Medicines

Every medicine of every company in the group, current ones first.

8 medicines

Medicine	Substance	Country	Status	Authorised
BILDYOS60 mg / ml · Solution	Denosumab	Canada	Authorised
BILDYOS60mg/ml · Injectable	Denosumab	United States	Marketed	2025
BILDYOS60 mg / ml · Solution	Denosumab	Canada	Marketed	2026
BILPREVDA120mg/1.7ml(70mg/ml) · Injectable	Denosumab	United States	Marketed	2025
Bilprevda120mg/1.7ml (70mg/ml) · Injection	Denosumab	United States	Marketed	2025
POHERDY420mg/14ml(30mg/ml) · Injectable	Pertuzumab	United States	Marketed	2025
TUZEMTY120 mg / 1.7 ml · Solution	Denosumab	Canada	Marketed	2026
Zercepac	Trastuzumab	Saudi Arabia	Authorised

Know your medicines, with the sources.

One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.

Join Prognia free

Countries

Where it holds or makes medicines, with how many are current.

Country	Medicines	Current	Companies
United States	4	4	Companies All medicines
Canada	3	3	Companies All medicines
Saudi Arabia	1	1	Companies All medicines

Also in the registers of Brazil, Singapore

Sources and licences

Compiled by Prognia from the public medicine and company registers below. Logos are not used.

Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.

U.S. Food and Drug Administration (Drugs@FDA, openFDA)

Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.

Licence: Public domain (U.S. Government work)

Anvisa, Brazil

Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.

Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions

Health Canada, Canada

Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.

Licence: Open Government Licence Canada

Health Canada, Canada

Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.

Licence: Open Government Licence Canada

Saudi Food and Drug Authority

Saudi Food and Drug Authority (SFDA), foreign human medicine open-data listing, source scope 2023, retrieved 11 October 2026 UTC; exact original file and response modification date retained.

Licence: Exact SFDA open-data section explicitly offers freely usable named human medicine workbooks; factual-data scope only

Health Sciences Authority / data.gov.sg

Contains information from HSA Listing of Registered Therapeutic Products accessed on 8 October 2026 from data.gov.sg, under Singapore Open Data Licence 1.0: https://data.gov.sg/open-data-licence

Licence: Singapore Open Data Licence

All 7 sources

U.S. Food and Drug Administration

FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.

Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions

Report an error or request removalCorrections from the company itself are welcome.

Henlius

Group structure

Headquarters not stated2

Medicines

Know your medicines, with the sources.

Countries

Therapeutic areas

Top substances

Names in the registers

Sources and licences

At a glance

Other big groups